Gain Therapeutics has FDA clearance for GT-02287, but can biomarkers become real benefit?
Find out how Gain Therapeutics’ GT-02287 could test GCase restoration as a disease-modifying strategy for Parkinson’s disease.
Pharma & Biotech
Medical Devices & Diagnostics
QT Imaging passed its first FDA inspection cleanly, but can adoption follow?
Find out how QT Imaging’s clean FDA inspection could support Breast Acoustic CT scale-up and breast imaging adoption.
Pharma & Biotech
Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.
Pharma & Biotech
Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech
Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.
Medical Devices & Diagnostics
Why Novanta’s June healthcare conference appearance matters after its Q1 revenue rebound
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.
Pharma & Biotech
Why Knox Lane is taking Cross Country Healthcare private in a $437m all-cash deal
Healthcare staffing is still under pressure. Knox Lane’s $437m Cross Country Healthcare deal turns that reset into a private equity wager.
Pharma & Biotech
Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.
Features & Analysis
Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.